Interleukin-1 antagonism in type 1 diabetes of long duration

Diabetes Metab. 2016 Dec;42(6):453-456. doi: 10.1016/j.diabet.2016.08.005. Epub 2016 Oct 5.

Authors

E Seelig¹, K Timper², C Falconnier³, R Stoeckli², S Bilz⁴, R Oram⁵, T J McDonald⁵, M Y Donath²

Affiliations

¹ Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland. Electronic address: [email protected].
² Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.
³ Division of Endocrinology, Diabetology and Metabolism, Medical University Clinic, Kantonsspital Baselland, Liestal, Switzerland.
⁴ Clinic for Endocrinology, Diabetes, Bone Disease and Metabolism, Kantonsspital St. Gallen, St. Gallen, Switzerland.
⁵ NIHR Exeter Clinical Research Facility, University of Exeter, Exeter, UK.

PMID: 27720360
DOI: 10.1016/j.diabet.2016.08.005

No abstract available

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Adolescent
Adult
Antibodies, Monoclonal, Humanized / therapeutic use
Blood Glucose / analysis
C-Peptide / blood
C-Peptide / metabolism
Chronic Disease
Diabetes Mellitus, Type 1 / drug therapy
Diabetes Mellitus, Type 1 / metabolism*
Glycated Hemoglobin / analysis
Humans
Insulin-Secreting Cells / metabolism
Insulin-Secreting Cells / physiology*
Interleukin-1beta / antagonists & inhibitors*
Interleukin-1beta / metabolism*
Middle Aged
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Blood Glucose
C-Peptide
Glycated Hemoglobin A
Interleukin-1beta
hemoglobin A1c protein, human
gevokizumab